Yagawa Yusuke, Kudo Shin-Ei, Miyachi Hideyuki, Mori Yuichi, Misawa Masashi, Sato Yuta, Kudo Koki, Ishigaki Tomoyuki, Ichimasa Katsuro, Kudo Toyoki, Hayashi Takemasa, Wakamura Kunihiko, Baba Toshiyuki, Ishida Fumio
Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa 224-8503, Japan.
Mol Clin Oncol. 2021 Apr;14(4):63. doi: 10.3892/mco.2021.2225. Epub 2021 Jan 29.
The European Society of Gastrointestinal Endoscopy does not recommend self-expanding metal stent (SEMS) placement as a bridge to surgery (BTS) for malignant colorectal obstruction (MCRO). However, no universally accepted consensus has been determined. The present study aimed to evaluate the short- and long-term outcomes of SEMS placement vs. emergency surgery (ES) for MCRO. Surgical resection of colorectal cancer was performed in 3,840 patients between April 2001 and June 2016. Of these, 93 patients had MCRO requiring emergency decompression. Only patients in whom the colorectal lesion was ultimately resected were included; thus, the present study included 62 patients treated with MCRO via SEMS placement as a BTS (n=25) or via ES (n=37). The rates of laparoscopic surgery, primary anastomosis, stoma formation, lymph node dissection, adverse events, 30-day mortality and disease-free survival were evaluated. The clinical success rate of SEMS placement was 92.0% (23/25). Compared with the ES group, the SEMS group had higher rates of laparoscopic surgery (68.0 vs. 2.7%; P<0.001) and primary anastomosis (88.0 vs. 51.4%; P=0.003), a greater number of dissected lymph nodes (30 vs. 18; P=0.001), and lower incidences of stoma formation (24.0 vs. 67.6%; P=0.002) and overall adverse events (24.0 vs. 62.2%; P=0.004). The 30-day mortality and disease-free survival of the SEMS group were not significantly different to that of the ES group (0 vs. 2.7%; P=1.000; log-rank test; P=0.10). In conclusion, as long as adverse events such as perforation are minimized, SEMS placement as a BTS could be a first treatment option for MCRO. The present study is registered in the University Hospital Medical Network Clinical Trials Registry (UMIN R000034868).
欧洲胃肠内镜学会不推荐将自膨式金属支架(SEMS)置入作为恶性大肠梗阻(MCRO)的手术过渡(BTS)方法。然而,尚未确定普遍接受的共识。本研究旨在评估SEMS置入与急诊手术(ES)治疗MCRO的短期和长期结果。2001年4月至2016年6月期间,对3840例患者进行了结直肠癌手术切除。其中,93例患者患有需要紧急减压的MCRO。仅纳入最终进行了结直肠病变切除的患者;因此,本研究纳入了62例通过SEMS置入作为BTS(n = 25)或通过ES(n = 37)治疗MCRO的患者。评估了腹腔镜手术、一期吻合、造口形成、淋巴结清扫、不良事件、30天死亡率和无病生存率。SEMS置入的临床成功率为92.0%(23/25)。与ES组相比,SEMS组的腹腔镜手术率(68.0%对2.7%;P<0.001)和一期吻合率(88.0%对51.4%;P = 0.003)更高,清扫的淋巴结数量更多(30个对18个;P = 0.0